The latest price target for Intra-Cellular Therapies (NASDAQ:ITCI) was reported by Piper Sandler on September 6, 2024. The analyst firm set a price target for $92.00 expecting ITCI to rise to within 12 months (a possible 25.43% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Intra-Cellular Therapies (NASDAQ:ITCI) was provided by Piper Sandler, and Intra-Cellular Therapies upgraded their overweight rating.

The last upgrade for Intra-Cellular Therapies Inc happened on September 6, 2024 when Piper Sandler raised their price target to $92. Piper Sandler previously had a neutral for Intra-Cellular Therapies Inc.

The last downgrade for Intra-Cellular Therapies Inc happened on June 25, 2024 when UBS changed their price target from $85 to $83 for Intra-Cellular Therapies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a upgraded with a price target of $68.00 to $92.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $73.35, which is within the analyst’s predicted range.